Ematoncologia

Discover a comprehensive and up-to-date reference resource for bone marrow pathology, complete with an extensive list of references The diagnosis and treatment of bone marrow pathologies is one of the most critical areas of medical research and care. For years, Bone Marrow Pathology has served as the essential reference and teaching tool in the field of haematology, with an authoritative treatment of the subject written by acknowledged leaders in the field. Now fully updated to reflect urgent new changes to the theory and practice of haematology, it promises to serve a new generation of practitioners. In the book, the characteristics and function of normal bone marrow are extensively discussed. Bone marrow pathology, including both aspirate films and trephine biopsy sections, is examined in a clinical context. The content is augmented by discussion of the peripheral blood findings and supplementary bone marrow tests. Readers of the sixth edition of Bone Marrow Pathology will also find: Lavish illustrations with high-quality images of bone marrow and other associated images Incorporation of new classifications including the WHO and International Consensus classifications, as well as new and expanded research areas Emphasis on practical tools including differential diagnosis and common problems and pitfalls A practical, integrated approach to diagnosis Perfect for trainee and consultant haematologists and haematopathologists, Bone Marrow Pathology will also prove itself invaluable for cytogeneticists, molecular geneticists and anyone working in immunophenotyping.

Developed by 149 experts in the field, The International Consensus Classification of Myeloid and Lymphoid Neoplasms provides key information for use at the microscope to assist in arriving at a swift and accurate diagnosis. Drs. Daniel Arber, Michael J. Borowitz, James Cook, Laurence de Leval, John Goodlad, Robert Hasserjian, Rebecca L. King, Hans-Michael Kvasnicka, and Attilio Orazi lead a team of authors who focus on diagnostic criteria and the clinical significance of each disease entity.   Offers up-to-date information developed through a Clinical Advisory Committee (CAC) process that included the authors and editors of the former 3rd, 4th, and revised 4th edition World Health Organization (WHO) classification of hematopoietic and lymphoid tumors Focuses on diagnostic criteria and includes guidelines as to the clinical significance of each disease authored by a clinician expert Provides essential information for pathologists and hematopathologists in practice and in training, as well as oncologists and hematologists who want to better understand the many disease categories that they encounter ,

Concise, portable, and user-friendly, The Washington Manual Hematology and Oncology Subspecialty Consult, 5th Edition, provides quick access to the essential information needed to evaluate a patient on a hematology-oncology subspecialty consult service. Edited by Drs. Brian A. Van Tine and Meagan A. Jacoby, this best-selling manual offers state-of-the-art content, including coverage of new therapies such as CAR T-cell therapy, new anti-cancer drugs, and new biomarkers and therapeutic targets. Ideal for fellows, residents, and medical students rotating on hematology and oncology subspecialty services, the manual is also useful as a first-line resource for advanced practice providers, general internal medicine physicians, Hem/ONC fellows, and other primary care providers. Thoroughly revised to include new therapies such as PD-1 inhibitors for Hodgkin lymphoma, CAR T-cell therapy in NHL and multiple myeloma, gene therapy for sickle cell disease, CAR T-cell therapies and management of CRS and neurotoxicity, and more It presents clinically oriented information like symptoms, signs, and problems in a quick-reference, bulleted list format for easy, everyday reference Shares the knowledge and experience of a new co-editor of the Hematology section, Dr. Meagan Jacoby Provides updated references for additional information on key topics Written by fellows and  faculty from the Washington University School of Medicine in St. Louis The Washington Manual® is a registered mark belonging to Washington University in St. Louis to which international legal protection applies. The mark is used in this publication by WoltersKluwer Health under license from Washington University. Enrich your eBook reading experience Read directly on your preferred device(s),such as computer, tablet, or smartphone. Easily convert to audiobook,powering your content with natural language text-to-speech.

High-risk acute myeloblastic leukemia (HR AML) is charac­terized by unfavorable biologic and clinical features impairing the efficacy of conventional treatments resulting in less than 40% short-term complete remission (CR) rate and poor median overall survival (OS). In addition, high-risk disease occurs, often, in elderly patients with high comorbidity burden and these findings induce poor tolerability to chemotherapy and reduced eligibility to allogeneic stem cell transplantation (HSCT), the only curative therapeutic option in this setting. Here, leading experts in the field cover all the novel aspects concerning the updated definition, the diagnosis, the management and future perspectives tor HR AML patients. Over the last decade the great progress in molecular and cell biology, medicinal chemistry far drug design and immunology have resulted in the development and approval of a large number of novel therapeutics for patients with AML. Although the definition of HR AML is evolving, the better understanding of the genetic and biological characteristics of leukemic cells and their microenviroment will significantly contribute towards novel therapeutic approaches.

**Selected for 2026 Doody's Core Titles in Transplantation Surgery** Led by authors from MD Anderson’s Stem Cell Transplantation and Cellular Therapy Department, the world’s largest and highly respected program at the forefront of rapidly advancing treatments in the field, Manual of Hematopoietic Cell Transplantation and Cellular Therapies is a comprehensive, focused reference covering the latest clinical developments and applications of stem cell transplant and cellular therapies for hematologic malignancies and solid tumors. This cutting-edge title, with a majority contribution from the MD Anderson Cancer Center and leading faculty from other academic institutions, covers breakthrough cell-based therapies for various diseases including lymphoma, multiple myeloma, leukemia, and select solid tumor and autoimmune diseases. This unique, definitive resource is essential for hematologists, fellows in hematology and immunotherapy, mid-level providers, pharmacists, and oncologists who refer patients for cell-based therapies. Addresses hematologic conditions including leukemia, lymphoma, and myeloma Offers guidance on hematopoietic cell transplantation for solid tumors Covers basic science principles, clinical aspects, pharmacology, radiation therapy, and disease-specific guidelines, including prevention and management of complications Discusses key topics such as hematopoietic cell collection, bone marrow harvesting, umbilical cord blood transplantation, CAR T-cell therapy, and patient/donor selection and preparation of HCT Features extensive summary boxes, bulleted content, and algorithms throughout for quick and easy reference Offers team-based, clinically-focused coverage from world-renowned leaders in the field An eBook version is included with purchase. The eBook allows you to access all of the text, figures and references, with the ability to search, customize your content, make notes and highlights, and have content read aloud

Il volume propone un viaggio nel mondo oncoematologico, un dialogo tra professionalità diverse che accoglie la voce dei pazien

For those preparing for certification or recertification in hematology or oncology, Hoffman and Abeloff's Hematology-Oncology Review is a single-volume source of authoritative, up-to-date exam preparation. This unique question and answer review helps you succeed on today's board exams with more than 1,000 board-style questions, answers, and rationales; comprehensive coverage of essential exam topics, and online practice tests.Includes 1,000+ board-style questions with answers and rationales explaining both correct and incorrect answers. Features three online practice tests per specialty that follow the ABIM exams blueprint, ensuring that complex content is delivered in easily digestible segments for more efficient review. Covers a broad range of topics compiled by experts in hematology and oncology, including cancer biology and genomics, immunotherapy, hematologic malignancies, solid tumor malignancies, non-malignant hematology, and supportive care. Uniquely designed as both a standalone review and a study companion to Abeloff's Clinical Oncology and Hematology: Basic Principles and Practice. Expert ConsultT eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, and references from the book on a variety of devices.

This issue compiled by Dr. Nancy Berliner focuses on such topics as: A History of Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation for Severe Combined Immune Deficiency Or What the Children have Taught Us; HLA-haploidentical Donor Transplantation in Severe Combined Immunodeficiency; Haploidentical Bone Marrow Transplantation in Primary Immune Deficiency - Stem Cell Selection and Manipulation; Suffering from Severe Combined Immunodeficiency; Herpes Viruses in Transplant Recipients: HSV,VZV, Human Herpes Viruses, and EBV; and, Immunotherapy and Vaccination After Transplant - The Present, the Future.

Progress in the treatment of cancer over the past two decades has been rapid with many new and novel therapeutic modalities arriving at an unprecedented pace. Overall cancer mortality rates have actually begun to fall in parallel with progress in the diagnosis and treatment of malignant disease. Despite our advances in the understanding of the biology and molecular genetics of cancer, as well as the availability of an increasing array of effective therapies, cancer treatment today and for the foreseeable future will include the traditional modalities of surgery, radiation therapy and chemotherapy. Myelosuppressive agents with their potential hematopoietic toxicities remain the mainstay of systemic treatment for both metastatic and early stage cancer. The complications of cancer chemotherapy have serious impact on a patient's well being and overall quality of life. Fortunately, advances in cancer treatment have been accompanied by equally impressive progress in the availability of a wide array of supportive care modalities which have greatly enhanced the ability of oncologists to minimize the impact of cancer and its treatment on patient quality of life as well improve delivery of potentially curative cancer treatment. Despite the increasing complexity of modern cancer treatment, it is the obligation of the oncologist as well as the entire cancer care team to be certain that cancer patients receive the optimal supportive care available for their disease and its treatment. Among the most serious and potentially life threatening toxicities of cancer treatment are the hematologic toxicities accompanying myelosuppression including anemia and associated asthenia and fatigue, neutropenia and fever associated with infection in the immunocompromised patient and thrombocytopenia and accompanying risk of bleeding. Special supportive care needs arise in the very elderly care patient that may tax the ability of even the most skilled clinician. Despite the considerable progress that has been made with more effective and safer treatment strategies, myelosuppressive chemotherapy will remain the mainstay of systemic treatment for cancer for the foreseeable future. While considerable progress has occurred, better methods and broader application of supportive care measures are needed to reduce the symptomatic effects of cancer and the associated toxicities associated with cancer treatment. No area of cancer supportive care better illustrates the progress that has resulted from advances in our understanding of cellular and molecular biology, genetic engineering and the development of more effective yet often more toxic cancer treatments than that of the hematopoietic growth factors. This volume will review and integrate the major advances in our understanding of the underlying molecular biology and pharmacology of these agents along with the results of well designed and executed randomized controlled trials of the erythroid stimulating agents, the myeloid growth factors and the new thrombopoietic agents each addressing a major threat associated with bone marrow suppression accompanying cancer treatment. The current clinical utilization of these agents is based on numerous randomized controlled trials and meta-analyses along with evidence-based clinical practice guidelines developed by professional societies guiding their appropriate and cost-effective use in clinical care.

Thoroughly updated for its second edition, "Non-Hodgkin Lymphomas" is the definitive textbook on the biology, diagnosis, staging, and treatment of all forms of non-Hodgkin lymphomas. With backgrounds in medical and radiation oncology, molecular biology, and pathology, the editors and contributors provide an international, multidisciplinary approach to the topic. This edition is the first text using the new World Health Organization classification of non-Hodgkin lymphomas. The book offers complete coverage of the most current techniques for diagnosis, staging, and treatment, the approach to specific types of lymphoma, and special problems common to the management of patients with these disorders. A companion Website includes the fully searchable text and downloadable images.

This book will assist pathologists, hematologists, and oncologists in interpreting peripheral blood and bone marrow specimens quickly, easily, and accurately. Featuring more than 400 full-color illustrations, the book is a very complete survey of bone marrow diseases, including rare entities, and provides up-to-date information on constitutional and acquired disorders in both adults and children. This edition includes the latest information on hematologic and associated diseases, including many new disease descriptions, recent genetic and immunologic findings, and the current World Health Organization classification of hematolymphoid disorders. A companion Website will offer the fully searchable text and an image bank.

This highly popular book in the proven question-and-answer format of the Secrets Series[registered] is better than ever in this completely updated new edition. The major sections are General Concepts, General Hematology, Malignant Hematology, Care of the Cancer Patient, and Solid Tumors. Concise, and yet comprehensive with over 90 chapters written by experts in the field, this book presents all the need-to-know key information and provides the insights, pearls, and "secrets" that are the hallmark of the series.

Innovative Leukemia and Lymphoma Therapy provides a complete and up-to-date overview of the exciting new treatment modalities in leukemia and lymphoma that are being introduced in the clinic today. Written by international experts in the field, this volume examines clinical studies on topics such as: tyrosine kinase inhibitors, histon deacetylase inhibitors, and farnesyl transferase inhibitors radioimmunotherapy, gene-directed therapy, and immunotherapy by vaccination monoclonal antibodies anti-angiogenesis approaches Within each chapter, this well-illustrated, comprehensive source provides a summary of the rationale for treatment, the pathways that are involved, and the translational research to students, scientists, and clinicians. In addition, this book focuses on the concerns of conventional but novel anticancer agents, modulation of classical multidrug resistance, and modulators of single agent drug resistance.

Now in its Fourth Edition, this comprehensive, practical, and thoroughly illustrated reference offers valuable guidance in the diagnostic interpretation of lymph node biopsies. It provides encyclopedic coverage of all the various nonmalignant lesions, lymphomas, other neoplasms, and metastatic tumors in lymph nodes. The discussion of each pathologic entity includes definition, clinical syndrome, histopathology, and differential diagnosis. This edition has more than 700 illustrations, including over 600 in full color. Dr. Ioachim is joined by a new co-editor, L. Jeffrey Medeiros, MD, from the University of Texas MD Anderson Cancer Center. All chapters have been extensively revised and a new chapter on genetics has been added. A companion Website will offer the fully searchable online text and an image bank.